Is subclinical adrenal failure in adrenoleukodystrophy/ adrenomyeloneuropathy reversible?

Journal of Endocrinological Investigation

Volumn 34, Issue 10, 2011, Pages 753-756

  Cappa, M ^a   Bizzarri, C ^a   Giannone, G ^a   Aiello, C ^a   Di Biase, A ^b  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

ACTH; Adrenal failure; Adrenoleulcodystrophy; Adrenomyeloneuropathy; Lorenzo's oil

Indexed keywords

CORTICOTROPIN; LORENZO OIL; STEROID; TETRACOSACTIDE; VERY LONG CHAIN FATTY ACID;

ADRENAL FUNCTION; ADRENAL INSUFFICIENCY; ADRENOLEUKODYSTROPHY; ADULT; ARTICLE; CLINICAL ARTICLE; CORTICOTROPIN BLOOD LEVEL; FOLLOW UP; HUMAN; LOW FAT DIET; STEROID THERAPY;

ADRENAL GLANDS; ADRENAL INSUFFICIENCY; ADRENOCORTICOTROPIC HORMONE; ADRENOLEUKODYSTROPHY; ADULT; DIETARY FATS; DRUG COMBINATIONS; ERUCIC ACIDS; FATTY ACIDS; HUMANS; HYDROCORTISONE; TRIOLEIN;

EID: 84856864788     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/7570     Document Type: Article

References (24)

1. Berger J, Gärtner J. X-linked adrenoleukodystrophy: clinical, biochemical and pathogenetic aspects. Biochim Biophys Acta 2006, 1763: 1721-32.
2. Kishimoto Y, Moser HW, Kawamura N, Platt M, Pallante SL, Fenselau C. Adrenoleukodystrophy: evidence that abnormal very long chain fatty acids of brain cholesterol esters are of exogenous origin. Biochem Biophys Res Commun 1980, 96: 69-76. (Pubitemid 11246642)
3. Tsuji S, Sano T, Ariga T, Miyatake T. Increased synthesis of hexacosanoic acid (C26:0) by cultured skin fibroblasts from patients with adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN). J Biochem 1981, 90: 1233-6. (Pubitemid 12174826)
4. Moser HW, Mahmood A, Raymond GV. X-linked adrenoleukodystrophy. Nat Clin Pract Neurol 2007, 3: 140-51. (Pubitemid 46403941)
5. Van Geel BM, Assies J, Wanders RJ, Barth PG. X-linked adrenoleukodystrohy: clinical presentation, diagnosis, and therapy. J Neurol Neurosurg Psychiatry 1997, 63: 4-14.
6. Blevins LS Jr, Shankroff J, Moser HW, Ladenson PW. Elevated plasma adrenocorticotropin concentration as evidence of limited adrenocortical reserve in patients with adrenomyeloneuropathy. J Clin Endocrinol Metab 1994, 78: 261-5. (Pubitemid 24061736)
7. Asheuer M, Bieche I, Laurendeau I, et al. Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy. Hum Mol Genet 2005, 14: 1293-303. (Pubitemid 40744489)
8. Whitcomb RW, Linehan WM, Knazek RA. Effects of long-chain, saturated fatty acids on membrane microviscosity and adrenocorticotropin responsiveness of human adrenocortical cells in vitro, J Clin Invest 1988, 81: 185-8. (Pubitemid 18092251)
9. Ho JK, Moser H, Kishimoto Y, Hamilton JA. Interactions of a very long chain fatty acid with model membranes and serum albumin. Implications for the pathogenesis of adrenoleukodystrophy. J Clin Invest 1995, 96: 1455-63.
10. Knazek RA, Rizzo WB, Schulman JD, Dave JR. Membrane microviscosity is increased in the erythrocytes of patients with adrenoleukodystrophy and adrenomyeloneuropathy. J Clin Invest 1983, 72: 245-8. (Pubitemid 13025865)
11. Fourcade S, Ruiz M, Camps C, et al. A key role for the peroxisomal ABCD2 transporter in fatty acid homeostasis. Am J Physiol Endocrinol Metab 2009, 296: E211-21.
12. Powers JM, Pei Z, Heinzer AK, et al. Adreno-leukodystrophy: oxidative stress of mice and men. J Neuropathol Exp Neurol 2005, 64: 1067-79.
13. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326:818-23.
14. Moser HW. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain 1997, 120: 1485-508. (Pubitemid 27344713)
15. Moser HW, Raymond GV, Lu SE, et al. Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil. Arch Neurol 2005, 62: 1073-80. (Pubitemid 41043727)
16. Cappa M, Cambiaso P, del Balzo P, Benedetti S, Borrelli P. Hormonal evalutation of adrenoleukodystrophy. In: Uziel G, Wanders RJA, Cappa M eds. Adrenoleukodystrophy and other peroxisomal disorders. Amsterdam: Elsevier. 1990, 81-92.
17. th ed. Philadelfia: Saunders Elsevier. 2008, 477-85.
18. Dubey P, Raymond GV, Moser AB, Kharkar S, Bezman L, Moser HW. Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening. J Pediatr 2005, 146: 528-32. (Pubitemid 40469718)
19. Powers JM, Schaumburg HH, Johnson AB, Raine CS. A correlative study of the adrenal cortex in adrenoleukodystrophy: evidence for a fatal intoxication with very long chain fatty acids. Invest. Cell Pathol 1980, 3: 353-76. (Pubitemid 11210963)
20. Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, et al. A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy. N Engl J Med 1993, 329: 745-52. (Pubitemid 23262528)
21. Rasmussen M, Moser AB, Borel J, Khangoora S, Moser HW. Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's oil). Neurochem Res 1994, 9: 1073-82. (Pubitemid 24243344)
22. Poulos A, Gibson R, Sharp P, Beckman K, Grattan-Smith P. Very long chain fatty acids in X-linked adrenoleukodystrophy brain after treatment with Lorenzo's oil. Ann Neurol 1994, 36: 741-6. (Pubitemid 24337633)
23. Golovko MY, Murphy EJ. Uptake and metabolism of plasma-derived erucic acid by rat brain. J Lipid Res 2006, 47: 1289-97. (Pubitemid 43830721)
24. Beuschlein F, Fassnacht M, Klink A, Allolio B, Reincke M. ACTH-receptor expression, regulation and role in adrenocortial tumor formation. Eur J Endocrinol 2001, 144: 199-206. (Pubitemid 32266286)